About Rennova Health (OTCMKTS:RNVA)
Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova's principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc.
Industry, Sector and Symbol
Industry Enterprise Software
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$5.24 million
Price / Sales0.09
Price / CashN/A
Book Value($79.74) per share
Price / Book0.00
Return on EquityN/A
Return on Assets-1,232.10%
Rennova Health (OTCMKTS:RNVA) Frequently Asked Questions
What is Rennova Health's stock symbol?
Rennova Health trades on the OTCMKTS under the ticker symbol "RNVA."
When did Rennova Health's stock split? How did Rennova Health's stock split work?
Rennova Health shares reverse split before market open on Friday, October 6th 2017. The 1-15 reverse split was announced on Friday, September 22nd 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Rennova Health stock prior to the reverse split would have 7 shares after the split.
How were Rennova Health's earnings last quarter?
Rennova Health, Inc. (OTCMKTS:RNVA) announced its quarterly earnings data on Monday, November, 20th. The company reported ($10.59) earnings per share for the quarter. The business earned $1.41 million during the quarter. View Rennova Health's Earnings History.
Who are some of Rennova Health's key competitors?
Who are Rennova Health's key executives?
Rennova Health's management team includes the folowing people:
- Seamus Lagan, President, Chief Executive Officer, Interim Chief Financial Officer, Director (Age 48)
- John B. Beach, Director (Age 55)
- Paul R. Billings M.D. Ph.D., Director (Age 63)
- Christopher E. Diamantis, Director (Age 48)
- James M. Karis, Director (Age 66)
- Robert P. Lee, Director (Age 62)
How do I buy Rennova Health stock?
Shares of Rennova Health can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rennova Health's stock price today?
One share of Rennova Health stock can currently be purchased for approximately $0.08.
How big of a company is Rennova Health?
Rennova Health has a market capitalization of $500,000.00 and generates $5.24 million in revenue each year. Rennova Health employs 116 workers across the globe.
How can I contact Rennova Health?
Rennova Health's mailing address is 400 S. Australian Avenue 8th Floor, West Palm Beach FL, 33401. The company can be reached via phone at 561-855-1626 or via email at [email protected]
MarketBeat Community Rating for Rennova Health (RNVA)MarketBeat's community ratings are surveys of what our community members think about Rennova Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Rennova Health (OTCMKTS:RNVA) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Rennova Health (OTCMKTS:RNVA) Earnings History and Estimates Chart
Rennova Health (OTCMKTS RNVA) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/20/2017||Q3 2017||($10.59)||$1.41 million||View||N/A|
|8/15/2017||Q2 2017||($20.55)||$0.90 million||View||N/A|
|11/14/2016||Q316||($15.00)||($4.35)||$5.89 million||$0.29 million||View||N/A|
|11/13/2014||($7.35)||($5.25)||$0.11 million||$0.18 million||View||N/A|
|8/14/2014||Q214||($7.35)||($9.15)||$0.06 million||$0.06 million||View||N/A|
Rennova Health (OTCMKTS:RNVA) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Rennova Health (OTCMKTS:RNVA)
No dividend announcements for this company have been tracked by MarketBeat.com
Rennova Health (OTCMKTS RNVA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.50%
Institutional Ownership Percentage: 19.29%
Rennova Health (OTCMKTS RNVA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/14/2016||Jason Adams||CFO||Buy||1,160||$0.28||$324.80|| |
|7/14/2016||Michael Louis Goldberg||Director||Buy||2,500||$0.28||$700.00|| |
|7/14/2016||Seamus Lagan||CEO||Buy||10,900||$0.38||$4,142.00|| |
|6/7/2016||Jason Adams||CFO||Buy||270||$0.75||$202.50|| |
|6/3/2016||Jason Adams||CFO||Buy||295||$0.63||$185.85|| |
|5/23/2016||Michael Louis Goldberg||Director||Buy||1,500||$0.61||$915.00|| |
|11/15/2013||Carl Muscari||Director||Buy||1,300||$3.85||$5,005.00|| |
|3/26/2013||Carl Muscari||Director||Buy||1,540||$3.25||$5,005.00|| |
|10/5/2012||Participations Alcatel-Lucent||Major Shareholder||Sell||149,200||$4.20||$626,640.00|| |
Rennova Health (OTCMKTS RNVA) News Headlines
Rennova Health (OTCMKTS:RNVA) SEC Filings
Rennova Health (OTCMKTS:RNVA) Income Statement, Balance Sheet and Cash Flow Statement
Rennova Health (OTCMKTS RNVA) Stock Chart for Tuesday, December, 12, 2017